MC4 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-21. Anything still debated is marked as such rather than presented as settled.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Xenon poisoning was a contributing factor to the Chernobyl disaster; during a run-down to a lower power, a combination of operator error and xenon poisoning caused the reactor thermal power to fall to near-shutdown levels. The crew's resulting efforts to restore power placed the reactor in a highly unsafe configuration. A flaw in the SCRAM system inserted positive reactivity, causing a thermal transient and a steam explosion that tore the reactor apart. Reactors using continuous reprocessing like many molten salt reactor designs might be able to extract 135Xe from the fuel and avoid these effects. Fluid fuel reactors cannot develop xenon inhomogeneity because the fuel is free to mix. Also, the Molten Salt Reactor Experiment demonstrated that spraying the liquid fuel as droplets through a gas space during recirculation can allow xenon and krypton to leave the fuel salts. Removing 135Xe from neutron exposure improves neutron economy, but causes the reactor to produce more of the long-lived fission product 135Cs. The long lived (but 76000 times less radioactive) caesium-135 condenses in a separate tank after the decay of 135Xe, and is physically separate from the 30.05-year-half-life caesium-137 (137Cs) produced in the fuel, and it is practical to handle them separately (fission yield is approximately 6% for both).
The underlying assumption was that psychopharmacology was at least as effective as psychotherapy, and it could be delivered more efficiently because less time is required for the appointment. Because of this shift in practice patterns, psychiatrists often refer patients whom they think would benefit from psychotherapy to other mental health professionals, e.g., clinical social workers and psychologists.
==== Active sensor methodologies ==== Satellite RADAR mapping is one of the major techniques of generating Digital Elevation Models (see below). Similar techniques are applied in bathymetric surveys using sonar to determine the terrain of the ocean floor. In recent years, lidar, a remote sensing technique that uses a laser instead of radio waves, has increasingly been employed for complex mapping needs such as charting canopies and monitoring glaciers.
== Possible therapies == Calorie restriction, vitamin E, and increased glutathione appear to reduce or halt the production of lipofuscin. The nootropic drug piracetam appears to significantly reduce accumulation of lipofuscin in the brain tissue of rats. Other possible treatments:
The presidency of Pedro Castillo began with Castillo's inauguration as the president of Peru on 28 July 2021, the Peruvian Independence Day. In the 2021 Peruvian general election, Castillo, a school teacher and union organizer, won the presidential election against the right-wing candidate Keiko Fujimori of Popular Force by a 45,000 margin in the runoff. In the congressional elections, Castillo's party, Free Peru, did not get a majority in the Congress of the Republic of Peru.
Sources: en.wikipedia.org
== External links == "Papers of John B. Fenn, 1948–2010 (bulk 1970–1990)". Science History Institute. Click on 'Fenn Papers Finding Aid 2014' for finding aid to archive. Interview where John Fenn discusses the history of the development of the Electrospray Ionization method Annual Reviews Conversations Interview with John B. Fenn (video) John B. Fenn on Nobelprize.org including the Nobel Lecture December 8, 2002 Electrospray Wings for Molecular Elephants Dudley R. Herschbach and Charles E. Kolb, "John B. Fenn", Biographical Memoirs of the National Academy of Sciences (2014)
== Further reading == Dean L (2017). "Risperidone Therapy and CYP2D6 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520384. Bookshelf ID: NBK425795.
Fibroin presents a unique combination of properties rarely found in one material. It is strong and tough, dissolves and reconstitutes in water rather than aggressive solvents, and breaks down in the body over a period that can be lengthened or shortened as required. Once the sericin is removed, it provokes only a mild immune response. A single quantity of purified protein can therefore be shaped into many different forms, each suited to a particular use. Until the late 1990s, reliable methods for dissolving silk fibres and forming the resulting solution were not available, and most of the work after that has been based on them. Silk biomaterials are used in tissue engineering, drug delivery, wound care and bioelectronics, and a small number have reached clinical use. The factors limiting them are specific: the raw material varies from batch to batch, silk is difficult to sterilise without damaging the protein, and production is hard to scale.
=== Chemical reactions === Changing the conditions of the reaction solvent can allow separation of phases for product removal, or single phase for reaction. Rapid diffusion accelerates diffusion controlled reactions. Temperature and pressure can tune the reaction down preferred pathways, e.g., to improve yield of a particular chiral isomer. There are also significant environmental benefits over conventional organic solvents. Industrial syntheses that are performed at supercritical conditions include those of polyethylene from supercritical ethene, isopropyl alcohol from supercritical propene, 2-butanol from supercritical butene, and ammonia from a supercritical mix of nitrogen and hydrogen. Other reactions were, in the past, performed industrially in supercritical conditions, including the synthesis of methanol and thermal (non-catalytic) oil cracking. Because of the development of effective catalysts, the required temperatures of those two processes have been reduced and are no longer supercritical.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.